Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 1 2

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 223Carboplatin 218Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 91Fluorouracil 87Bevacizumab 83Nivolumab 74Leucovorin 72Rituximab 70Vincristine 67durvalumab 66Lenalidomide 63Etoposide 62atezolizumab 61Radiation 61Irinotecan 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × 10-propargyl-10-deazaaminopterin × 1 year × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07234162 2025-11-18

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Dizal Pharmaceuticals

Phase 3 Recruiting
218 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06072131 2025-10-23

CRESCENDO

Acrotech Biopharma Inc.

Phase 3 Recruiting
504 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡